Picard Medical Reports Reduced Losses in Q3
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Should l Buy PMI?
Source: NASDAQ.COM
Financial Performance: Picard Medical, Inc. reported a narrowed loss per share of $0.19 in Q3, compared to $0.87 the previous year, while revenue increased to $1.19 million from $0.88 million.
EBIT and EBITDA Losses: The EBIT loss widened to $10.43 million from $6.21 million, but the EBITDA loss narrowed to $3.49 million from $4.44 million year-over-year.
Market Reaction: In pre-market trading, shares of Picard Medical fell by 3.69%, trading at $2.3500 on the New York Stock Exchange.
Disclaimer: The views expressed in the report are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PMI
About PMI
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faruqi & Faruqi Investigates Securities Fraud at Picard Medical
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud at Picard Medical, urging investors who purchased securities between September 2 and October 31, 2025, to contact them for legal support to protect their rights.
- Stock Price Plunge: On October 24, 2025, Picard Medical's shares plummeted from $13.20 to $5.31, a drop of $7.89 or 59.8%, marking one of the most significant single-day declines since the company's IPO, which could undermine investor confidence.
- False Promotion Allegations: The complaint alleges that Picard and its executives violated federal securities laws by failing to disclose involvement in a fraudulent stock promotion scheme and insider trading activities, potentially exposing investors to significant losses.
- Class Action Deadline: Faruq & Faruqi reminds investors that the deadline to apply as lead plaintiff in the federal securities class action is April 13, 2026, allowing interested investors to ensure their rights to any potential recovery through legal counsel.
See More
Faruqi & Faruqi Encourages Investors in Picard Medical to Reach Out
- Legal Investigation: Faruq & Faruq LLP is investigating potential claims against Picard Medical, particularly for investors who purchased securities between September 2, 2025, and October 31, 2025, indicating possible legal risks that could undermine shareholder confidence.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing multiple contact options to help them understand their legal rights and take necessary actions.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against Picard Medical is April 13, 2026, which may affect their ability to file claims.
- Potential Market Impact: The initiation of this legal investigation could negatively impact Picard Medical's stock price, prompting investors to closely monitor developments to adjust their investment strategies accordingly.
See More
Picard Medical Faces Class Action for Securities Fraud
- Lawsuit Background: Pomerantz LLP has filed a class action lawsuit against Picard Medical, alleging that the company and certain officers engaged in securities fraud or other unlawful business practices, with investors needing to apply as Lead Plaintiff by April 3, 2026.
- Stock Price Surge: Leading up to October 23, 2025, Picard's stock price skyrocketed from its IPO price of $4.00 to an all-time high of $13.68, despite the absence of any fundamental news to justify such a dramatic increase, indicating irrational market behavior.
- Social Media Manipulation: Investigations revealed that Picard's stock was subject to an illicit social media promotion scheme, where impersonators posing as legitimate financial advisors made sensational but unfounded claims, creating a buying frenzy among retail investors that artificially inflated the stock price.
- Law Firm Credentials: Pomerantz LLP is recognized as a premier class action firm with over 85 years of experience in corporate and securities litigation, having secured numerous multimillion-dollar settlements for class members, underscoring its expertise in handling securities fraud cases.
See More
Class Action Notice for Picard Medical Securities Purchasers
- Class Action Deadline: The lead plaintiff deadline for the Picard Medical securities class action is April 13, 2026, requiring investors to apply by this date to represent other investors in the litigation.
- Lawsuit Background: The lawsuit alleges that Picard Medical made materially false and misleading statements from September 2 to October 31, 2025, failing to disclose significant adverse facts about its business and securities trading, resulting in investor losses.
- Legal Counsel Selection: Investors are encouraged to choose qualified legal counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal support in the class action.
- Historical Performance: Rosen Law Firm has recovered over $438 million for investors in 2019 alone and achieved the largest securities class action settlement against a Chinese company in 2017, demonstrating its strong capabilities in securities class actions.
See More
Multiple Companies Face Class Action Lawsuits
- Richtech Robotics Lawsuit: Richtech Robotics Inc. is facing allegations for failing to disclose its non-existent collaboration with Microsoft during the class period from January 27 to January 29, 2026, misleading investors about the company's prospects, with a lead plaintiff motion deadline set for April 3, 2026.
- Picard Medical Allegations: Picard Medical, Inc. is accused of being involved in a fraudulent stock promotion scheme from September 2 to October 31, 2025, failing to disclose critical information that undermined investor confidence, with the same lead plaintiff motion deadline of April 3, 2026.
- Plug Power Legal Issues: Plug Power, Inc. is under scrutiny for allegedly overstating the availability of funds related to a DOE loan during the period from January 17 to November 13, 2025, misleading investors about future projects, with a lead plaintiff motion deadline of April 3, 2026.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz encourage affected investors to reach out for legal advice regarding their rights, providing contact details including phone and email for inquiries.
See More
Picard Medical Investors Advised on Class Action Lawsuit
- Class Action Notice: The Portnoy Law Firm advises Picard Medical investors of a class action lawsuit for those who purchased securities between September 5 and October 31, 2025, with a deadline of April 3, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Stock Price Crash: The complaint reveals that Picard's stock price plummeted 70% on October 24, 2025, from $13.30 to $3.99 per share, and has since continued to decline to approximately $2.00, indicating a severe loss of market confidence in the company.
- Fraud Allegations: The lawsuit alleges that Picard failed to disclose its involvement in a fraudulent stock promotion scheme utilizing social media misinformation, and insiders used offshore accounts to facilitate coordinated share dumping, significantly harming investor interests.
- Legal Support: The Portnoy Law Firm offers complimentary case evaluations to assist investors in recovering losses due to corporate wrongdoing, with its founding partner having successfully recovered over $5.5 billion for aggrieved investors, showcasing its strong legal expertise.
See More
Faruqi & Faruqi Investigates Securities Fraud at Picard Medical
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud at Picard Medical, urging investors who purchased securities between September 2 and October 31, 2025, to contact them for legal support to protect their rights.
- Stock Price Plunge: On October 24, 2025, Picard Medical's shares plummeted from $13.20 to $5.31, a drop of $7.89 or 59.8%, marking one of the most significant single-day declines since the company's IPO, which could undermine investor confidence.
- False Promotion Allegations: The complaint alleges that Picard and its executives violated federal securities laws by failing to disclose involvement in a fraudulent stock promotion scheme and insider trading activities, potentially exposing investors to significant losses.
- Class Action Deadline: Faruq & Faruqi reminds investors that the deadline to apply as lead plaintiff in the federal securities class action is April 13, 2026, allowing interested investors to ensure their rights to any potential recovery through legal counsel.
See More
Faruqi & Faruqi Encourages Investors in Picard Medical to Reach Out
- Legal Investigation: Faruq & Faruq LLP is investigating potential claims against Picard Medical, particularly for investors who purchased securities between September 2, 2025, and October 31, 2025, indicating possible legal risks that could undermine shareholder confidence.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing multiple contact options to help them understand their legal rights and take necessary actions.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against Picard Medical is April 13, 2026, which may affect their ability to file claims.
- Potential Market Impact: The initiation of this legal investigation could negatively impact Picard Medical's stock price, prompting investors to closely monitor developments to adjust their investment strategies accordingly.
See More
Picard Medical Faces Class Action for Securities Fraud
- Lawsuit Background: Pomerantz LLP has filed a class action lawsuit against Picard Medical, alleging that the company and certain officers engaged in securities fraud or other unlawful business practices, with investors needing to apply as Lead Plaintiff by April 3, 2026.
- Stock Price Surge: Leading up to October 23, 2025, Picard's stock price skyrocketed from its IPO price of $4.00 to an all-time high of $13.68, despite the absence of any fundamental news to justify such a dramatic increase, indicating irrational market behavior.
- Social Media Manipulation: Investigations revealed that Picard's stock was subject to an illicit social media promotion scheme, where impersonators posing as legitimate financial advisors made sensational but unfounded claims, creating a buying frenzy among retail investors that artificially inflated the stock price.
- Law Firm Credentials: Pomerantz LLP is recognized as a premier class action firm with over 85 years of experience in corporate and securities litigation, having secured numerous multimillion-dollar settlements for class members, underscoring its expertise in handling securities fraud cases.
See More
Class Action Notice for Picard Medical Securities Purchasers
- Class Action Deadline: The lead plaintiff deadline for the Picard Medical securities class action is April 13, 2026, requiring investors to apply by this date to represent other investors in the litigation.
- Lawsuit Background: The lawsuit alleges that Picard Medical made materially false and misleading statements from September 2 to October 31, 2025, failing to disclose significant adverse facts about its business and securities trading, resulting in investor losses.
- Legal Counsel Selection: Investors are encouraged to choose qualified legal counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal support in the class action.
- Historical Performance: Rosen Law Firm has recovered over $438 million for investors in 2019 alone and achieved the largest securities class action settlement against a Chinese company in 2017, demonstrating its strong capabilities in securities class actions.
See More
Multiple Companies Face Class Action Lawsuits
- Richtech Robotics Lawsuit: Richtech Robotics Inc. is facing allegations for failing to disclose its non-existent collaboration with Microsoft during the class period from January 27 to January 29, 2026, misleading investors about the company's prospects, with a lead plaintiff motion deadline set for April 3, 2026.
- Picard Medical Allegations: Picard Medical, Inc. is accused of being involved in a fraudulent stock promotion scheme from September 2 to October 31, 2025, failing to disclose critical information that undermined investor confidence, with the same lead plaintiff motion deadline of April 3, 2026.
- Plug Power Legal Issues: Plug Power, Inc. is under scrutiny for allegedly overstating the availability of funds related to a DOE loan during the period from January 17 to November 13, 2025, misleading investors about future projects, with a lead plaintiff motion deadline of April 3, 2026.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz encourage affected investors to reach out for legal advice regarding their rights, providing contact details including phone and email for inquiries.
See More
Picard Medical Investors Advised on Class Action Lawsuit
- Class Action Notice: The Portnoy Law Firm advises Picard Medical investors of a class action lawsuit for those who purchased securities between September 5 and October 31, 2025, with a deadline of April 3, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Stock Price Crash: The complaint reveals that Picard's stock price plummeted 70% on October 24, 2025, from $13.30 to $3.99 per share, and has since continued to decline to approximately $2.00, indicating a severe loss of market confidence in the company.
- Fraud Allegations: The lawsuit alleges that Picard failed to disclose its involvement in a fraudulent stock promotion scheme utilizing social media misinformation, and insiders used offshore accounts to facilitate coordinated share dumping, significantly harming investor interests.
- Legal Support: The Portnoy Law Firm offers complimentary case evaluations to assist investors in recovering losses due to corporate wrongdoing, with its founding partner having successfully recovered over $5.5 billion for aggrieved investors, showcasing its strong legal expertise.
See More
